Pretax income is the income that a company earns before paying income taxes. Kiora Pharmaceuticals's pretax income for the
three
months ended in Dec. 2024 was $-2.16 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $5.66 Mil.
Kiora Pharmaceuticals's pretax margin was %.
During the past 13 years, Kiora Pharmaceuticals's highest Pretax Margin was 35.38%. The lowest was -57083.33%. And the median was -1321.65%.
Kiora Pharmaceuticals Pre-Tax Income Historical Data
The historical data trend for Kiora Pharmaceuticals's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Kiora Pharmaceuticals's Pre-Tax Income
For the Biotechnology subindustry, Kiora Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kiora Pharmaceuticals's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kiora Pharmaceuticals's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Kiora Pharmaceuticals's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.66 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiora Pharmaceuticals (NAS:KPRX) Pre-Tax Income Explanation
Kiora Pharmaceuticals's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as
During the past 13 years, Kiora Pharmaceuticals's highest Pretax Margin was 35.38%. The lowest was -57083.33%. And the median was -1321.65%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiora Pharmaceuticals Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Kiora Pharmaceuticals's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KPRX has been successfully added to your 